Nilsson, Fredrik O. L. http://orcid.org/0000-0002-1905-4047
Asanin, Sandra T.
Masters, Elizabeth T.
Iadeluca, Laura
Almond, Chrissy
Cooper, Miranda
Smith, Sarah
Funding for this research was provided by:
Pfizer Inc
Article History
Accepted: 6 March 2021
First Online: 3 June 2021
Declarations
:
: This study was sponsored by Pfizer Inc. Medical writing support was funded by Pfizer.
: F. Nilsson is an employee of Pfizer Innovations AB and holds Pfizer Inc. stock and stock options. S.T. Asanin is an employee of Pfizer Innovations AB and holds Pfizer Inc. stock and stock options. E.T. Masters is an employee of Pfizer Inc. and holds Pfizer Inc. stock and stock options. L. Iadeluca is an employee of Pfizer Inc. and holds Pfizer shares, stock, and stock options. C. Almond, M. Cooper, and S. Smith are employees of BresMed. BresMed received consultancy fees from Pfizer Inc. for the development of the global cost-effectiveness model for lorlatinib and supporting statistical analyses. The authors did not receive direct payment as a result of this work outside of their normal salary payments.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: FN, CA, MC, SS, and STA were involved in the conception and design of the study. All authors contributed to the analysis or interpretation of data for this work, contributed in drafting or revising it critically for important intellectual content, and approved the final version.